KR960010622B1 - Method of extraction and purification for active substances from ginko herb - Google Patents

Method of extraction and purification for active substances from ginko herb Download PDF

Info

Publication number
KR960010622B1
KR960010622B1 KR1019920022987A KR920022987A KR960010622B1 KR 960010622 B1 KR960010622 B1 KR 960010622B1 KR 1019920022987 A KR1019920022987 A KR 1019920022987A KR 920022987 A KR920022987 A KR 920022987A KR 960010622 B1 KR960010622 B1 KR 960010622B1
Authority
KR
South Korea
Prior art keywords
ginkgo biloba
acetone
extract
added
solution
Prior art date
Application number
KR1019920022987A
Other languages
Korean (ko)
Other versions
KR940013519A (en
Inventor
강승안
김종권
박경호
Original Assignee
유유산업 주식회사
유승필
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유유산업 주식회사, 유승필 filed Critical 유유산업 주식회사
Priority to KR1019920022987A priority Critical patent/KR960010622B1/en
Publication of KR940013519A publication Critical patent/KR940013519A/en
Application granted granted Critical
Publication of KR960010622B1 publication Critical patent/KR960010622B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The purification method of Ginko extracts (I) consists of (1) dissolving crude (I) in 50% ethanol solution, and (2) filtrating with ultrafiltration membranes in the range of 3000- 10000 dalton to discard protein, polysaccharide and proanthicyanins. (I) is safe for use.

Description

은행잎으로부터 유효활성물질을 추출정제하는 방법Extraction and Purification of Active Active Substances from Ginkgo Leaves

제1도, 제2도 및 제3도는 본 발명의 방법에 따른 실시예 1, 2 및 8에서 추출정제된 유효활성물질중 프로안토시아니딘 화합물에 대해 정량 분석결과로 나타난 흡수극대 곡선을 각각 비교예 2의 경우와 비교 도시한 그래프이고,1, 2 and 3 respectively show absorption maximum curves as quantitative analysis results of proanthocyanidin compounds in the active substances extracted and purified in Examples 1, 2 and 8 according to the method of the present invention. It is a graph compared with the case of Comparative Example 2,

제4도와 제5도는 본 발명의 방법에 따른 실시예 2에서 추출정제된 분말과 표준품에 대해 각각 고속액체 크로마토그래피를 이용하여 유효활성물질의 량을 정량적으로 분석한 크로마토그램이다.4 and 5 are chromatograms for quantitatively analyzing the amounts of active substances using high-performance liquid chromatography, respectively, for powders and standard products extracted in Example 2 according to the method of the present invention.

본 발명은 은행잎으로부터 유효생리활성물질을 추출정제하는 방법에 관한 것으로서, 더욱 상세하게는 은행잎으로부터 혈관 및 혈액순환장애와 노인성 질환치료에 사용될 수 있는 유효생리활성물질을 추출하되 유해성 물질을 사용하지 않고서도 간단하고 경제적인 방법으로 고농도의 유효활성물질을 추출정제하는 방법에 관한 것이다.The present invention relates to a method for extracting and purifying an effective physiologically active substance from ginkgo biloba, and more particularly, to extract an effective physiologically active substance which can be used for the treatment of vascular and blood circulation disorders and senile diseases from ginkgo biloba without using harmful substances. The present invention also relates to a method for extracting and purifying high concentrations of active substances in a simple and economical way.

일반적으로 은행잎에 함유되어 있는 깅고 플라본 유효성분들은 여러가지 유효를 나타내므로 은행잎 추출물을 이용한 의약품이나 건강식품등이 개발되고 있다.In general, the active gingo flavones contained in the ginkgo biloba has various effects, so drugs or health foods using ginkgo biloba extract have been developed.

구체적으로 은행잎 추출물은 혈관확장 작용을 타나내고 혈류촉진 작용에 의하여 말초혈류 및 뇌 혈류량을 현저히 증가시키고 인체 조직내에서 ATP의 농도를 증가시켜 준다. 또한 세포내의 에너지 대사를 촉진시키는 것도 알려지고 있다. 그 외에도 뇌허혈증, 뇌말초 혈관확장 작용과 각종 저산소증에 탁월한 예방 및 치료효과가 있는 것으로 밝혀져서, 이러한 효능으로 인해 그 이용이 더욱 증가되고 있다.Specifically, ginkgo biloba extract exhibits vasodilation and significantly increases peripheral blood flow and brain blood flow by blood flow promoting action and increases the concentration of ATP in human tissue. It is also known to promote energy metabolism in cells. In addition, it is found that there is an excellent prevention and treatment effect on cerebral ischemia, peripheral cerebral vasodilation and various hypoxia, and its use is further increased due to such efficacy.

이러한 은행잎으로부터 유효성분을 추출해 내는 방법은 기존에 여러방법이 알려져 있다.There are several known methods for extracting the active ingredient from the ginkgo leaves.

예컨대, 일본특허공고 소46-28091호 및 49-27323호에서는 은행잎 추출물을 제조하는 방법으로 디클로로메탄, 클로로포름, 사염화탄소와 같은 할로겐화 탄화수소를 용매로 하여 유효성분을 추출정제하는 방법이 개시되어 있다. 그러나, 이런방법은 그 사용용매가 의약품에서 매우 바람직하지 않은 유해물이기 때문에 정제과정에 세심한 주의가 필요하고 또는 환경문제를 유발시킬 수 있을 뿐 아니라 추출정제에 관여하는 작업자에게 직접적인 폐해도 우려된다. 더우기, 일본특허공고 소49-27323호에서는 추출과정에서 유독한 납화합물이 사용되고 있기 때문에 바람직하지 못한 것으로 지적되고 있다.For example, Japanese Patent Publication Nos. 46-28091 and 49-27323 disclose a method of extract-purifying an active ingredient using a halogenated hydrocarbon such as dichloromethane, chloroform and carbon tetrachloride as a method for preparing a ginkgo leaf extract. However, this method requires careful attention to the purification process or can cause environmental problems because the solvent is a very undesirable pest in pharmaceuticals, and it is also a concern for direct harm to the workers involved in extraction purification. Furthermore, Japanese Patent Publication No. 49-27323 points out that it is not preferable because toxic lead compounds are used in the extraction process.

특히, 일본특허공고 소46-28091호에서의 은행잎 추출물은 경구투여제로는 적당하나 유효활성 성분의 안정성을 손상시키는 미지의 물질을 제거해야 주사제로 사용할 수 있다고 했으며, 그 미지물질을 제거하는 처리수단을 찾아야 한다고 기술되어 있다.In particular, Ginkgo biloba extract in Japanese Patent Publication No. 46-28091 is suitable as an oral administration agent, but it can be used as an injection only when an unknown substance that impairs the stability of the active ingredient is removed. It is stated that must be found.

또, 일본특허공고 소49-27323호에서는 소46-28091호에서 언급한 유효활성물질의 안정성을 손상시키는 미지의 물질이 용액상태에서 침전을 발생시킨다는 사실을 발견했으며 침전을 유발시키는 원인이 프로델피니딘임을 언급하고 있으나, 이를 제거하여 추출물중의 잔류량을 저하시키는 추출방법으로 유해물질인 납화합물을 사용하고 있다.In addition, Japanese Patent Publication No. 49-27323 found that an unknown substance that impairs the stability of the active substance mentioned in SO 46-28091 causes precipitation in solution, and the cause of precipitation is prodelpinidine. Although it is mentioned, the lead compound which is a harmful substance is used as an extraction method to reduce the residual amount in the extract by removing it.

또한, 국내에서도 특허공고 제81-333호 및 제90-5318호 및 제90-5319호 등의 은행잎 엑기스 추출방법이 있는 바, 특허공고 제81-333호의 경구 상기 일본특허공고 소49-27323호와 실질적으로 같은 방법으로서, 할로겐화 탄화수소와 초산납 또는 수산화납을 사용하는 방법으로 위와 같은 문제가 있다.In addition, there are methods of extracting ginkgo biloba extracts, such as Japanese Patent Publication Nos. 81-333, 90-5318, and 90-5319, and the Japanese Patent Publication No. 49-27323 of Patent Publication No. 81-333. As substantially the same method as above, there is a problem as described above using a halogenated hydrocarbon and lead acetate or lead hydroxide.

다만, 국내특허공고 제90-5318호와 제90-5319호의 경우 기존의 방법을 개선한 공정을 보여주고 있으나, 전자인 국내특허공고 제90-5318호는 정제과정으로 정제칼럼을 사용하고 있으며 이 칼럼의 제조시 할로겐화 지방족 탄화수소인 사염화탄소를 사용하고 있는 문제가 있고, 후자인 국내특허공고 제90-5319호의 경우는 일부 개선점이 평가할만 하지만 비스무스 화합물을 사용하기 때문에 역시 주의가 필요하다.However, in the case of Korean Patent Publication Nos. 90-5318 and 90-5319, an improved method of the existing method is shown, but the former Korean Patent Publication No. 90-5318 uses a purified column as a purification process. There is a problem of using carbon tetrachloride, which is a halogenated aliphatic hydrocarbon, in the preparation of the column, and the latter Korean Patent Publication No. 90-5319 can evaluate some improvement points, but it is also necessary to pay attention because it uses bismuth compounds.

이와 같이, 기존에 알려진 은행잎 엑기스 추출물을 제조하는 방법들은 모두가 할로겐화 탄화수소나 유해성 중금속 화합물을 이용하고 있어서 인체 유해성문제나 환경오염의 문제와 공정상의 세심한 주의가 필요한 문제등으로 인해 개선의 여지가 많았다.As described above, all known methods of preparing ginkgo biloba extract extracts have a lot of room for improvement due to problems of human hazards, environmental pollution, and problems that require careful attention in the process because they all use halogenated hydrocarbons or harmful heavy metal compounds. .

이에 본 발명자들은 이러한 종래방법에서 사용되었던 유독성 유기용매나 중금속 화합물을 전혀 사용하지 않고서 은행잎으로부터 유효성분을 추출정제하는 방법을 연구한 결과, 은행잎 추출물에서 침전을 생성하는 원인이 되는 물질을 분명하게 규명해 내고, 이를 토대로 종래사용된 바 없는 한외여과법을 이용하면 유해한 물질을 사용치 않을 뿐아니라 공정을 크게 단축시키면서 경제적으로 고순도의 은행잎 추출물을 추출정제해낼 수 있다는 사실을 알게되어 본 발명을 완성하였다.Therefore, the present inventors have studied the method of extracting and purifying the active ingredient from the ginkgo biloba without using any toxic organic solvents or heavy metal compounds used in the conventional method, and clearly identified the substance causing the precipitation in the ginkgo biloba extract. By using the ultrafiltration method, which has not been used before, based on this, it was found that not only harmful substances are used, but also the extract of purified ginkgo biloba extract can be economically extracted while greatly shortening the process, thereby completing the present invention.

따라서, 본 발명은 은행잎으로부터 유효성분을 추출정제함에 있어서, 무해성 유기용매를 사용하고 한외여과 방법을 이용하여서 고순도의 은행잎 추출물을 고수율로 제조하는 새로운 방법을 제공하는데 그 목적이 있다.Accordingly, an object of the present invention is to provide a new method for producing high purity ginkgo biloba extract in high yield by using a harmless organic solvent and using ultrafiltration in extracting and purifying the active ingredient from the ginkgo biloba leaves.

이하, 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.

본 발명은 은행잎을 메탄올 또는 물과 아세톤 또는 알코올의 혼합용액으로 추출하고 무기염을 가한다음, 유기용매로 다시 추출한 후, 얻어진 조엑기스로부터 불순물을 제거하여 유효활성물질을 추출정제함에 있어서, 상기 조엑기스로부터 불순물이 제거된 추출물을 얻기 위하여 그 조엑기스를 감압농축하여 얻은 잔류물에 에탄올 수용액을 첨가한 다음 한외여과막을 통과시키고, 그 통과된 용액을 에탄올 수용액으로 처리한 후 감압건조하여서 분말상으로 제조함을 그 특징으로 한다.The present invention extracts ginkgo biloba leaves with a mixture of methanol or water and acetone or alcohol and adds an inorganic salt, followed by extraction with an organic solvent, and then removing impurities from the crude extract obtained to extract and purify the active substance. To obtain an extract from which the impurities were removed from the extract, the crude extract was concentrated under reduced pressure, and then ethanol aqueous solution was added to the residue, which was passed through an ultrafiltration membrane, and the resulting solution was treated with an aqueous ethanol solution and dried under reduced pressure to obtain a powder. It is characterized by.

이와 같은 본 발명을 더욱 상세히 설명하면 다음과 같다.Referring to the present invention in more detail as follows.

본 발명은 은행잎으로부터 종래의 방법에 의해 혼합용매 또는 유기용매로 추출하여 조추출물을 제조하고 난 다음, 이를 한외여과 방법으로 추출정제하는 것에 특징을 두고 있다.The present invention is characterized in that the crude extract is prepared by extracting from the ginkgo biloba with a mixed solvent or an organic solvent by a conventional method, followed by extraction and purification by ultrafiltration.

본 발명에 따르면, 건조된 은행잎을 메탄올 또는 물과, 아세톤이나 메탄올, 에탄올 또는 프로판올과 같은 알코올의 혼합용액으로 상온 또는 용매의 비점온도에서 추출한다. 이렇게 얻어진 추출액을 찌꺼기와 분리한다음 감압하에서 유기용매를 제거하여 전체중량의 10% 이하로 농축한다. 이때 필요하면 추출액에서 유기성분을 치환하기 위해서 물을 첨가할 수 있다. 위와 같이 농축된 추출농축액에 물을 가하여 건조 추출물이 전체 수용액에 10∼20중량%가 되도록 희석시킨 다음, 20℃이하로 냉각한 후 지용성 성분을 침전시켜 여과하여 제거하고 맑은 수용액에 염화나트륨 또는 황산암모늄을 교반하면서 20∼30%의 부피량으로 가한다. 이 용액에 추출용매로서 메틸에틸케톤 또는 메틸에틸케톤과 아세톤의 혼합유기용액을 가하고 방치한다. 이때 혼합 유기용액을 사용하는 경우는 메틸에틸케톤 : 아세톤의 비율이 부피비로 9 : 1 내지 4 : 6이 되도록 혼합 사용하며 이렇게 방치한 상태에서 두층으로 분리되면 유기용매층에 은행잎의 유효활성물질이 다량 함유된 상태로 얻어지며, 이를 감압하여서 고형분이 전체 용액의 50중량%가 되도록 농축하여 조엑기스를 얻는다.According to the present invention, the dried ginkgo biloba leaves are extracted with methanol or water and a mixed solution of alcohol such as acetone or methanol, ethanol or propanol at room temperature or boiling point temperature of the solvent. The extract thus obtained is separated from the residue and the organic solvent is removed under reduced pressure and concentrated to 10% or less of the total weight. At this time, water may be added to replace the organic component in the extract if necessary. Water was added to the concentrated extract concentrate as described above, and the dried extract was diluted to 10-20 wt% in the total aqueous solution. After cooling to 20 ° C. or lower, the fat-soluble component was precipitated and removed by filtration. Is added in a volume of 20-30% with stirring. Methyl ethyl ketone or a mixed organic solution of methyl ethyl ketone and acetone is added to this solution and left to stand. In this case, when the mixed organic solution is used, the ratio of methyl ethyl ketone: acetone is 9: 1 to 4: 6 in volume ratio. When the mixture is separated into two layers in this state, the active substance of ginkgo biloba leaves in the organic solvent layer It is obtained in the state containing a large quantity, and it concentrates so that solid content may be 50 weight% of the total solution by depressurizing this, and a crude extract is obtained.

본 발명에 따르면 이 농축된 조엑기스에 50v/v% 에탄올 수용액을 첨가하여 고형성분이 5∼20중량%가 되도록 희석한 다음, 은행잎 추출물의 조엑기스에 함유된 단백질, 다당류, 폴리페놀 중합체인 프로안토시아니딘 화합물과 같은 중합체를 효과적으로 제거하기 위해 상기 희석된 용액을 약 3,000∼10,000달톤의 배제한계를 가진 한외여과막을 통과시켜 유효활성물질만 추출한다.According to the present invention, a 50v / v% ethanol aqueous solution is added to the concentrated crude extract to dilute the solid component to 5 to 20% by weight, and then a protein, a polysaccharide, and a polyphenol polymer contained in the crude extract of the ginkgo biloba extract. To effectively remove polymers such as anthocyanidin compounds, the diluted solution is passed through an ultrafiltration membrane with an exclusion limit of about 3,000 to 10,000 Daltons to extract only the active substance.

이때 한외여과막의 배제한계가 3,000달톤 보다 낮아지면 유효활성물질들의 추출효과가 떨어져서 수율이 크게 저하되며, 10,000달톤 보다 높게되면 유효활성물질의 수득량은 많아지지만 중합체의 제거효율이 크게 떨어져서 최종 추출물중에 불순물인 프로안토시아니딘 화합물이 다량 잔류하기 때문에 순도가 나빠지는 문제가 있다.At this time, if the exclusion limit of the ultrafiltration membrane is lower than 3,000 Daltons, the extraction effect of the active active substances is lowered, and the yield is greatly lowered. If the upper limit is higher than 10,000 Daltons, the yield of the active active substances is increased, but the removal efficiency of the polymer is greatly decreased, and thus Since a large amount of the proanthocyanidin compound as an impurity remains, there is a problem of deterioration in purity.

본 발명에서 사용한 한외여과막은 상기 용액을 통과시켜서 용액중에 용해되어 있는 물질의 분자들을 크기에 따라 분리하기 위해 사용되는 매우 얇고 선택적인 여과막으로, 특정크기 이상의 고분자물질을 걸러내서 정제하므로써 용매를 포함한 대부분의 작은 분자들을 정량적으로 통과시키는 분자 여과막이다.The ultrafiltration membrane used in the present invention is a very thin and selective filtration membrane used to separate molecules of a substance dissolved in the solution according to the size by passing through the solution. Most of the ultrafiltration membranes include a solvent by filtering and purifying a polymer having a specific size or more. Molecular filtration membrane that quantitatively passes small molecules of.

이러한 한외여과막은 생명공학 분야에서의 연구영역을 넘어서 백신등 의약품의 제조공정에 사용하며 그 예로서 백신과 인터페론 제조시 배양된 고농도의 세포를 배지에서 분리하고 있고, 단백질등 생체고분자의 농축과 세척(desalting), 적혈구 용해물질중의 헤모글로빈과 효소와의 분리 및 콜로이드 미생물등 발열성물질(pyrogen)의 제거에 사용하고 있다.These ultrafiltration membranes are used in the manufacturing process of pharmaceuticals such as vaccines beyond the research field in biotechnology. For example, high concentrations of cells cultured during vaccine and interferon production are separated from the medium, and the concentration and washing of biopolymers such as proteins It is used for destingting, separating hemoglobin and enzymes from erythrocyte lysates and removing pyrogen such as colloidal microorganisms.

본 발명에서는 위와 같이 분자량에 따른 분획이 가능한 한외여과막을 이제까지 전혀 고려된 바 없는 천연물의 추출에 새롭게 이용하므로써 기존의 공지된 방법보다 더욱 간단하게 매우 고순도의 유효활성물질을 얻을 수 있다는 놀라운 사실을 알게 되었다.In the present invention, by using a new ultrafiltration membrane that can be fractionated according to the molecular weight as described above for the extraction of natural products that have never been considered at all, it is surprising to know that it is possible to obtain a very high purity of the active substance more simply than the existing known method It became.

즉, 본 발명에서는 기존에 천연물에서의 유효활성 성분의 추출에 사용된 바 없었던 한외여과 방법을 사용하므로써 종래의 방법과 비교할때 상변화(phase change)에 따른 화학적 물성변화의 우려가 전혀 없으므로 보다 안정적이고 은행잎 유효활성 성분인 플라본 글리코사이드가 고농도로 함유되어 있으면서 단백질, 당류, 프로안토시아니딘류 등의 고분자 불순물은 거의 없는 매우 고순도의 추출물을 얻게 되었다.That is, in the present invention, by using an ultrafiltration method that has not been used for the extraction of active ingredients from natural products in the past, there is no fear of chemical property change due to a phase change as compared with the conventional method. And high concentration of flavone glycoside, an active ingredient of ginkgo biloba leaves, and very high purity extract with little polymer impurities such as proteins, sugars and proanthocyanidins was obtained.

따라서, 이러한 한외여과막을 통과시키게 되면 고분자물질이 농축된 부분과 이런 고분자물질이 거의 들어있지 아니한 부분을 동시에 분리하여 얻을 수 있으므로 추출 및 정제효과가 좋으며, 특히 본 발명에서는 분자량 약 3,000∼10,000달톤의 배제한계를 갖는 것을 사용하므로써 단백질, 다당류 및 폴리페놀 중합체와 같은 중합체를 통과시키지 않게 되므로 본 발명에서 필요로 하는 유효활성물질만을 선택적으로 추출해낼 수 있다. 이렇게 사용한 후 한외여과막은 수세하여 반복 재사용도 가능하며, 한외여과시 어떠한 전처리 공정도 필요없고, 특별한 조건없이 상온에서 가능하다.Therefore, when passing through the ultrafiltration membrane can be obtained by simultaneously separating the portion of the concentrated polymer material and the portion containing little such polymer material is good extraction and purification effect, in particular in the present invention molecular weight of about 3,000 ~ 10,000 Daltons The use of those having an exclusion limit prevents the passage of polymers such as proteins, polysaccharides and polyphenol polymers, so that only the active substances required by the present invention can be selectively extracted. After use, the ultrafiltration membrane is washed with water and can be reused repeatedly. In case of ultrafiltration, no pretreatment process is required, and at room temperature without special conditions.

이와 같이, 본 발명에 따라 한외여과막으로 추출한 추출액은 감압하에 농축하고, 다시한번 85∼95v/v% 에탄올 수용액에 용해시킨 다음, 상온에서 하룻밤 정도 정치시키면 침전이 생기고 이것을 여과하면 맑은 여액을 얻게 되는데, 이 과정은 상기 한외여과막 추출이전에 혼합유기용액을 이용하여 추출할 때에 혼입된 물로 인해서 추출이후까지 추출액중에 남아있게 되는 용존 황산암모늄을 제거하기 위한 것이며, 이 과정을 거쳐 얻은 여액은 감압건조시켜서 잔류수분이 5중량%이하인 분말로 목적물을 얻는다.Thus, the extract extracted with the ultrafiltration membrane according to the present invention is concentrated under reduced pressure, and once again dissolved in 85 ~ 95v / v% ethanol aqueous solution, and then allowed to stand overnight at room temperature to precipitate, which is filtered to obtain a clear filtrate. , This process is to remove dissolved ammonium sulfate remaining in the extract until the extraction due to the water mixed when the extraction using the mixed organic solution before the ultrafiltration membrane extraction, the filtrate obtained through this process is dried under reduced pressure The target product is obtained with a powder having a residual moisture of 5% by weight or less.

이와 같은 과정을 거쳐 얻어진 목적물인 은행잎 유효활성물질은 퀘르세틴 글리코사이드, 캠프페롤 글리코사이드, 이소람네틴 글리코사이드 등의 플라본 글리코사이드의 함량이 다량 함유된 등황색의 무정형 흡습성 분말로서, 침전 형성물질인 프로안토시아니딘 화합물의 함량이 크게 저하된 고순도의 추출물을 고수율로 얻게되며, 통상의 방법에 따라 경구용액제, 주사용제제로 사용하더라도 침전등의 생성이 전혀 생기지 않는다. 이는 경구용액제나 주사용제제로 사용시 침전의 생성으로 인해 안정성에 영향을 주는 폴리페놀 중합체인 프로안토시아니딘 화합물을 비롯하여 단백질이나 다당류 등의 제반 불순물을 한꺼번에 한외여과 방식으로 제거시켜 주기 때문에 매우 간단한 공정으로 순도를 높여주므로써 액제나 주사제로 사용가능한 것이다.The ginkgo biloba active active material obtained through the above process is an orange-yellow amorphous hygroscopic powder containing a large amount of flavone glycosides such as quercetin glycosides, camphorol glycosides, and isoramnetine glycosides. High purity extract with high content of anthocyanidin compound is greatly reduced, and no precipitation is produced even when used as an oral solution or injectable solution according to a conventional method. This is very simple because it removes all impurities such as proanthocyanidin, a polyphenolic polymer that affects stability due to the formation of precipitates when used as an oral solution or an injectable solution at once, by ultrafiltration. By increasing the purity of the process can be used as a liquid or injection.

결국, 본 발명에서는 기존에 은행잎 추출물의 안정성을 저해하는 침전 형성물질이 프로델피니딘이라는 사실을 명확히 규명하기 위해 부단히 연구한 결과, 침전 형성물질이 프로델피니딘을 비롯하여 프로시아니딘등 프로안토시아니딘 화합물이 모두 안정성을 저해하는 침전 형성물질이라는 새로운 사실을 규명해 내고, 이들 침전 형성물질이 함유되지 아니한 은행잎 추출물을 제조하기 위해 종래 천연물 추출에는 물론 은행잎으로부터 유효활성물질의 추출에 전혀 사용된 바 없는 한외여과법을 사용하여 상기 침전 형성물질인 고중합 프로안토시아니딘 화합물이 거의 모두 제거된 은행잎 추출물을 간단하게 추출정제하여 목적을 달성할 수 있게 된 것이다.As a result, in the present invention, as a result of constant research to clarify the fact that the precipitate forming material that inhibits the stability of the ginkgo biloba extract is prodelpinidine, all of the proanthocyanidin compounds such as prodelinidine and procyanidin are found in the precipitate forming material. To identify new facts that precipitate stability hinders stability and to prepare ginkgo biloba extracts that do not contain these precipitate forming substances, ultrafiltration has not been used for extraction of active substances from ginkgo biloba as well as conventional natural product extraction. It is possible to achieve the purpose by simply extract purification of the ginkgo biloba extract, which almost all of the high-polymerization proanthocyanidin compound of the precipitate-forming material is removed.

상술한 바와 같이 본 발명에 따라 한외여과법으로 추출하므로써 간단하고 개선된 공정을 통해 고순도, 고수율로 은행잎 추출물을 얻을 수 있는 바, 종래에 추출방법과 비교하여 본 발명에서만 특징적으로 나타나는 효과를 열거하면 다음과 같다.As described above, by extracting by ultrafiltration according to the present invention, the ginkgo biloba leaf extract can be obtained with a high purity and high yield through a simple and improved process. As follows.

첫째, 종래에 거의 모든 추출방법에서 사용되었던 유해물질을 사용하지 않는다.First, it does not use harmful substances that have been conventionally used in almost all extraction methods.

둘째, 혼합용매추출 후 복잡한 불순물제거 공정이 크게 단축되었다.Second, the complex impurity removal process was greatly shortened after the mixed solvent extraction.

셋째, 주사제 제조시 침전 형성물질의 프로안토시아니딘 화합물임을 밝혀내고 이를 거의다 제거하므로써 순도를 크게 개선시켰다.Third, it was found to be a proanthocyanidin compound of the precipitate-forming material in the preparation of the injection and greatly improved the purity by removing almost all of it.

넷째, 주사제 제조시 침전 형성물질이 제거된 고순도의 은행잎 추출물을 제공하므로써 부작용 없이 액제나 주사액으로서 이용 가능한 원료를 제공할 수 있게 되었다.Fourth, by providing a high-purity ginkgo leaf extract from which the precipitate-forming substance is removed during the preparation of the injection, it is possible to provide a raw material that can be used as a liquid or injection without side effects.

다섯째, 최종 추출물중에 함유된 유효활성물질인 플라본 글리코사이드의 함량을 높은 수준으로 유지하면서도 추출수율을 크게 향상시켜 고수율로 목적화합물을 얻게 되었다.Fifth, while maintaining the content of flavone glycoside, an active active substance contained in the final extract at a high level, the extraction yield was greatly improved to obtain the target compound in high yield.

여섯째, 추출시 사용된 한외여과막은 수세하여 재사용 가능하기 때문에 경제적으로도 유리하다.Sixth, the ultrafiltration membrane used for extraction is economically advantageous because it can be washed and reused.

일곱째, 한외여과법으로 추출시 온도조건이나 특별한 전처리 과정없이 간단한 공정으로 추출이 가능하다.Seventh, it is possible to extract by a simple process without temperature conditions or special pretreatment during extraction by ultrafiltration.

이하, 본 발명을 실시예에 거의 상세히 설명하면 다음과 같은 바, 본 발명이 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples, but the present invention is not limited by the Examples.

실시예 1Example 1

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 930ml을 잎분말이 침출되도록 넣는다. 12시간 경과후 가압 여과하고 여액을 감압하에 총량이 150ml되도록 농축시킨다. 농축액에 물을 가해 200ml로 하고 격렬하게 교반한 후 12시간 동안 15℃로 냉각시켜 방치한 후 상등액을 침전물과 분리여과한다.100 g of dried ginkgo biloba leaves are filled in a cone container and 930 ml of 60v / v% acetone aqueous solution is added to leach the leaf powder. After 12 hours, the resultant was filtered under pressure and the filtrate was concentrated under reduced pressure to a total amount of 150 ml. Water was added to the concentrated solution to make 200 ml, the mixture was stirred vigorously, cooled to 15 ° C. for 12 hours, and the supernatant was separated and filtered.

여액을 교반하면서 황산암모늄 50g을 가하고 15분 후에 메틸에틸케톤 37ml와 아세톤 25ml 혼합용액을 가하여 혼합교반 후 정치시켜 유기용매층을 분리한 후 동량의 메틸에틸케톤과 아세톤 혼합용액으로 3회 반복추출하여 분리하여 합한다. 메틸에틸케톤, 아세톤층을 총량이 10g 되도록 감압하에 농축시킨다.After stirring the filtrate, 50 g of ammonium sulfate was added, and after 15 minutes, 37 ml of methyl ethyl ketone and 25 ml of acetone were added thereto, and the mixture was left to stir after mixing. The organic solvent layer was separated, and the mixture was repeatedly extracted three times with the same amount of methyl ethyl ketone and acetone. Separate and add. The methyl ethyl ketone and acetone layers are concentrated under reduced pressure so that the total amount is 10 g.

얻어진 농축액에 50v/v% 에탄올 수용액 68ml를 가해 용해시킨 후 4기압의 압력으로 아미콘사의 다이아플로(R) 한외여과막(Amicon’s Diaflo Ultrafiltration Menbranes) YM3(배제한계 : 3,000달톤)로 여과시킨다. 여액을 감압하여 5g이 되도록 농축시키고 90v/v% 에탄올 수용액 25ml로 용해시켜 상온에서 1일밤 방치한 후 맑게 여과하고 최대 60℃로 감압하에 건조시킨다. 2.16g의 유효활성물질(등황색분말)을 얻는다.68 ml of 50v / v% ethanol aqueous solution was added to the obtained concentrate, followed by dissolution, followed by filtration with Amicon's Diaflo Ultrafiltration Membranes YM3 (exclusion limit: 3,000 Daltons) at a pressure of 4 atm. The filtrate was concentrated under reduced pressure to 5 g, dissolved in 25 ml of 90v / v% ethanol aqueous solution, and allowed to stand at room temperature overnight. The filtrate was filtered clearly and dried under reduced pressure to a maximum of 60 ° C. 2.16 g of active active material (orange yellow powder) are obtained.

실시예 2Example 2

상기 실시예 1과 동일하게 실시하되 배제한계가 5,000달톤인 한외여과막을 사용하여 목적물을 얻었다. 이런 과정을 7회 반복하여 얻은 결과는 다음 표 1과 같았으며, 그 결과 2.2g의 유효활성물질(등황색분말)을 얻었다.The target product was obtained in the same manner as in Example 1, but using an ultrafiltration membrane having an exclusion limit of 5,000 Daltons. The results obtained by repeating this process seven times were as shown in Table 1 below, and as a result, 2.2 g of an active substance (orange powder) was obtained.

*상기 단위는 최종 목적물내에 함유된 유효활성물질의 함량에 대한 단위임.* The above unit is the unit of content of the active substance contained in the final target product.

실시예 3Example 3

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 대신에 메탄올 930ml를 사용한 것을 제외하고는 상기 실시예 2와 동일하게 실시하여 2.17g의 유효활성물질(등황색분말)을 얻었다.100 g of dried ginkgo biloba powder was filled into a cone container, and the same procedure as in Example 2 was carried out except that 930 ml of methanol was used instead of an aqueous 60v / v% acetone solution to obtain 2.17 g of an active substance (orange powder).

실시예 4Example 4

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 대신에 60v/v% 메탄올 수용액 930ml를 사용한 것을 제외하고는 상기 실시예 2와 동일하게 실시하여 2.54g의 유효활성물질(등황색분말)을 얻었다.2.54 g of active active material (orange powder) was prepared in the same manner as in Example 2 except that 100 g of dried ginkgo biloba powder was filled in a cone container and 930 ml of 60v / v% methanol aqueous solution was used instead of 60v / v% acetone aqueous solution. Got.

실시예 5Example 5

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 대신에 60v/v% 에탄올 수용액 930ml를 사용한 것을 제외하고는 상기 실시예 2와 동일하게 실시하여 2.2g의 유효활성물질(등황색분말)을 얻었다.An active material of 2.2 g (orange powder) was prepared in the same manner as in Example 2 except that 100 g of dried ginkgo biloba powder was filled into a cone container and 930 ml of an aqueous 60v / v% ethanol solution was used instead of an aqueous 60v / v% acetone solution. Got.

실시예 6Example 6

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 대신에 60v/v% 이소프로판올 수용액 930ml를 사용한 것을 제외하고는 상기 실시예 2와 동일하게 실시하여 1.66g의 유효활성물질(등황색분말)을 얻었다.1.66 g of an active substance (orange powder) was prepared in the same manner as in Example 2 except that 100 g of dried ginkgo biloba powder was filled into a cone container and 930 ml of an aqueous 60v / v% isopropanol solution was used instead of an aqueous 60v / v% acetone solution. Got.

실시예 7Example 7

상기 실시예 2와 동일하게 실시하되 한외여과막을 통과시킨 다음, 여과된 에탄올 수용액을 반분량으로 감압농축하고 황산암모늄 50g을 가하고 15분후 메틸에틸케톤 37ml와 아세톤 25ml 혼합용액을 가하여 혼합교반 후 정치시켜 유기용매층을 분리한 후 동량의 메틸에틸케톤과 아세톤 혼합용액으로 3회 반복 추출 분리하여 합한다.The same procedure as in Example 2 was carried out, but after passing through the ultrafiltration membrane, the filtrated aqueous solution of ethanol was concentrated under reduced pressure to half the amount, and 50 g of ammonium sulfate was added. After 15 minutes, 37 ml of methyl ethyl ketone and 25 ml of acetone were added thereto, followed by mixing and stirring. After separating the organic solvent layer, the mixture was extracted and separated three times by the same amount of methyl ethyl ketone and acetone mixed solution.

메틸에틸케톤과 아세톤층을 감압하여 총량이 5g이 되도록 농축시키고 90v/v% 에탄올 수용액 25ml로 용해시켜 상온에서 1일밤 방치한 후 맑게 여과하여 최대 60℃로 감압하에 건조시킨다. 1.95g의 유효활성물질(등황색분말)을 얻었다.The methyl ethyl ketone and acetone layer was reduced in pressure to a total amount of 5 g, dissolved in 25 ml of 90v / v% ethanol aqueous solution, and allowed to stand at room temperature overnight, then filtered clearly and dried under reduced pressure at a maximum of 60 ° C. 1.95 g of an active substance (orange powder) was obtained.

실시예 8Example 8

상기 실시예 2와 동일하게 실시하되 베제한계가 10,000달톤인 한외여과막을 사용하여 3.17g의 유효활성물질(황갈색분말)을 얻었다.In the same manner as in Example 2, 3.17 g of an active substance (yellowish brown powder) was obtained using an ultrafiltration membrane having a bezel limit of 10,000 Daltons.

참고예Reference Example

상기 실시예 1과 동일하게 실시하되 배제한계가 1,000달톤인 한외여과막을 사용하여 0.67g의 유효활성물질(등황색분말)을 얻었다.In the same manner as in Example 1, 0.67 g of an active substance (orange powder) was obtained using an ultrafiltration membrane having an exclusion limit of 1,000 Daltons.

비교예 1Comparative Example 1

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 930ml을 잎분말이 침출되도록 넣는다. 12시간 경과후 가압 여과한뒤 여액을 감압하에 총량이 150ml되도록 농축시킨다. 농축액에 물을 가해 200ml로 하고 격렬하게 교반한 후 12시간 동안 15℃로 냉각시켜 방치한 후 상등액을 침전물과 분리여과한다. 여액을 교반하면서 황산암모늄 50g을 가하고 15분 후에 메틸에틸케톤 37ml와 아세톤 25ml 혼합용액을 가하여 혼합교반 후 정치시켜 유기용매층을 분리한 후 동량의 메틸에틸케톤과 아세톤 혼합용액으로 3회 반복추출하여 분리하여 합한다. 메틸에틸케톤, 아세톤층을 감압하에 농축시킨다. 얻어진 잔류물을 90v/v% 에탄올 수용액 25ml로 용해시켜 상온에서 1일밤 방치한 후 맑게 여과하고 최대 60℃로 감압하여 건조한다. 그 결과 3.7g 유효활성물질(갈색분말)을 얻었다.100 g of dried ginkgo biloba leaves are filled in a cone container and 930 ml of 60v / v% acetone aqueous solution is added to leach the leaf powder. After 12 hours, the resultant was filtered under pressure, and the filtrate was concentrated to 150 ml under reduced pressure. Water was added to the concentrated solution to make 200 ml, the mixture was stirred vigorously, cooled to 15 ° C. for 12 hours, and the supernatant was separated and filtered. After stirring the filtrate, 50 g of ammonium sulfate was added, and after 15 minutes, 37 ml of methyl ethyl ketone and 25 ml of acetone were added thereto, and the mixture was left to stir after mixing. The organic solvent layer was separated, and the mixture was repeatedly extracted three times with the same amount of methyl ethyl ketone and acetone. Separate and add. The methyl ethyl ketone and acetone layer are concentrated under reduced pressure. The residue obtained is dissolved in 25 ml of 90v / v% ethanol aqueous solution, and is allowed to stand at room temperature overnight. The resulting residue is filtered clearly and dried under reduced pressure at a maximum of 60 ° C. As a result, 3.7 g effective active material (brown powder) was obtained.

비교예 2Comparative Example 2

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 930ml을 잎분말이 침출되도록 넣는다. 12시간 경과후 가압 여과한뒤 여액을 사염화탄소 100ml씩 3회 추출하여 수성아세톤층을 각별히 분리한다. 이 수성아세톤층을 감압하여 150ml되도록 농축시킨다. 이 용액에 물을 가해 200ml로 하고 격렬하게 교반한 후 12시간 동안 15℃로 냉각시켜 방치한 후 상등액을 침전물과 분리여과한다. 여액을 교반하면서 황산암모늄 50g을 가하고 15분 후에 메틸에틸케톤과 아세톤 혼합용액으로 3회 반복 추출분리하여 합한다. 메틸에틸케톤, 아세톤층을 감압하에 농축시킨다. 얻어진 잔류물을 90v/v% 에탄올 수용액 25ml로 용해시켜 상온에서 1일밤 방치한 후 맑게 여과하고 최대 60℃로 감압하여 건조한다. 그 결과 3.13g의 유효활성물질(갈색분말)을 얻었다.100 g of dried ginkgo biloba leaves are filled in a cone container and 930 ml of 60v / v% acetone aqueous solution is added to leach the leaf powder. After 12 hours of filtration, the filtrate was extracted three times with 100 ml of carbon tetrachloride to separate the aqueous acetone layer. The aqueous acetone layer is concentrated under reduced pressure to 150 ml. Water was added to this solution to make 200 ml, the mixture was stirred vigorously, left to cool at 15 ° C. for 12 hours, and the supernatant was separated and filtered. 50 g of ammonium sulfate was added while stirring the filtrate, and after 15 minutes, the mixture was extracted and separated three times with methyl ethyl ketone and acetone mixed solution. The methyl ethyl ketone and acetone layer are concentrated under reduced pressure. The residue obtained is dissolved in 25 ml of 90v / v% ethanol aqueous solution, and is allowed to stand at room temperature overnight. The resulting residue is filtered clearly and dried under reduced pressure at a maximum of 60 ° C. As a result, 3.13 g of an active substance (brown powder) was obtained.

비교예 3Comparative Example 3

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 930ml을 잎분말이 침출되도록 넣는다. 이 수성아세톤층을 감압하에 총량이 150ml 되도록 농축시킨다. 농축액에 물을 가해 200ml로 하고 격렬하게 교반한 후 12시간 동안 15℃로 냉각시켜 방치한 후 상등액을 침전물과 분리여과한다. 여액을 교반하면서 황산암모늄 50g을 가하고 15분 후에 메틸에틸케톤과 아세톤 혼합용액으로 3회 반복추출분리하여 합한다. 메틸에틸케톤, 아세톤층을 총량 10g 되도록 감압하에 농축시킨다.100 g of dried ginkgo biloba leaves are filled in a cone container and 930 ml of 60v / v% acetone aqueous solution is added to leach the leaf powder. The aqueous acetone layer is concentrated under reduced pressure to a total amount of 150 ml. Water was added to the concentrated solution to make 200 ml, the mixture was stirred vigorously, cooled to 15 ° C. for 12 hours, and the supernatant was separated and filtered. While stirring the filtrate, 50 g of ammonium sulfate was added, and after 15 minutes, the mixture was repeatedly separated and separated three times with a mixture of methyl ethyl ketone and acetone. The methyl ethyl ketone and acetone layers were concentrated under reduced pressure to a total amount of 10 g.

얻어진 농축액에 50v/v% 에탄올 수용액 68ml를 가해 용해시킨 후 10% 초산납[Pb(COOCH)·3HO]수용액 30ml를 가하고 교반한 뒤에 정치시키고 형성된 침전물을 여과하여 제거한다. 에탄올 수용액을 반부량으로 감압농축하고 황산암모늄 50g을 가하고 15분 후에 메틸에틸케톤 37ml와 아세톤 25ml 혼합용액을 가하여 혼합교반 후 정치시켜 유기용매층을 분리한 후 동량의 메틸에틸케톤과 아세톤 혼합용액으로 3회 반복 추출분리하여 합한다. 메틸에틸케톤, 아세톤층을 총량이 10g되도록 감압하에 농축시킨다. 얻어진 농축액을 90v/v% 에탄올 수용액 25ml로 용해시켜 상온에서 1일밤 방치한 후 맑게 여과하고 최대 60℃로 감압하여 건조한다. 그 결과 1.22g 유효활성물질(등황색분말)을 얻었다.68 ml of a 50v / v% ethanol aqueous solution was added to the obtained concentrate, followed by dissolution. 30 ml of a 10% aqueous solution of lead acetate [Pb (COOCH) .3HO] was added thereto, stirred, and left to stand. The precipitate formed was filtered off. Concentrate the aqueous solution of ethanol under reduced pressure in half, add 50 g of ammonium sulfate, and after 15 minutes, add 37 ml of methyl ethyl ketone and 25 ml of acetone, and after stirring, separate the organic solvent layer, and then use an equal amount of methyl ethyl ketone and acetone. Extract three times and combine. The methyl ethyl ketone and acetone layers are concentrated under reduced pressure so that the total amount is 10 g. The obtained concentrated solution was dissolved in 25 ml of 90v / v% ethanol aqueous solution, left at room temperature for one night, then filtered clearly and dried under reduced pressure up to 60 ° C. As a result, 1.22 g effective active material (orange yellow powder) was obtained.

비교예 4Comparative Example 4

은행잎 건조분말 100g을 원추용기에 채워놓고 60v/v% 아세톤 수용액 930ml을 잎분말이 침출되도록 넣는다. 이 수성아세톤층을 감압하에 총량이 150ml 되도록 농축시킨다. 농축액에 물을 가해 200ml로 하고 격렬하게 교반한 후 12시간 동안 15℃로 냉각시켜 방치한 후 상등액을 침전물과 분리여과한다. 여액을 교반하면서 황산암모늄 50g을 가하고 15분 후에 메틸에틸케톤과 아세톤 혼합용액으로 3회 반복 추출분리하여 합한다. 메틸에틸케톤, 아세톤층을 총량 10g 되도록 감압하에 농축시킨다.100 g of dried ginkgo biloba leaves are filled in a cone container and 930 ml of 60v / v% acetone aqueous solution is added to leach the leaf powder. The aqueous acetone layer is concentrated under reduced pressure to a total amount of 150 ml. Water was added to the concentrated solution to make 200 ml, the mixture was stirred vigorously, cooled to 15 ° C. for 12 hours, and the supernatant was separated and filtered. 50 g of ammonium sulfate was added while stirring the filtrate, and after 15 minutes, the mixture was extracted and separated three times with methyl ethyl ketone and acetone mixed solution. The methyl ethyl ketone and acetone layers were concentrated under reduced pressure to a total amount of 10 g.

얻어진 농축액에 50v/v% 에탄올 수용액 68ml를 가해 용해시킨 후 10% 초산납[Pb(COOCH)·3HO]수용액 30ml를 가하고 교반한 뒤에 정치시키고 형성된 침전물을 여과하여 제거한다. 에탄올 수용액을 약 5g을 감압농축하고 얻어진 농축액을 90v/v% 에탄올 수용액 25ml로 용해시켜 상온에서 1일밤 방치한 후 맑게 여과하고 최대 60℃로 감압하여 건조한다. 그 결과 1.11g 유효활성물질(진황색분말)을 얻었다.68 ml of a 50v / v% ethanol aqueous solution was added to the obtained concentrate, followed by dissolution. 30 ml of a 10% aqueous solution of lead acetate [Pb (COOCH) .3HO] was added thereto, stirred, and left to stand. The precipitate formed was filtered off. About 5 g of an ethanol aqueous solution was concentrated under reduced pressure, and the obtained concentrated solution was dissolved in 25 ml of 90v / v% ethanol aqueous solution, and allowed to stand at room temperature for one night, then filtered clearly and dried under reduced pressure to a maximum of 60 ° C. As a result, 1.11 g effective active material (dark yellow powder) was obtained.

실험예 1Experimental Example 1

상기 실시예 1∼8 및 참고예에서 얻어진 분말을 상기 비교예 1∼4에서 얻어진 분말과 함께 자외/가시흡수 분광광도계를 이용하여 유효활성물질중에 액제나 주사제 제조시 침전생성을 일으키는 폴리페놀 중합체인 잔류 프로안토시아니딘 화합물의 함량을 확인하기 위해 정량적으로 분석하였다.The powders obtained in Examples 1 to 8 and Reference Examples, together with the powders obtained in Comparative Examples 1 to 4, are polyphenol polymers that produce precipitates in the preparation of liquids or injectables in effective active materials using an ultraviolet / visible absorption spectrophotometer. Quantitative analysis was performed to determine the content of residual proanthocyanidin compounds.

이중에서, 유해물질인 초산납을 사용하지 않고 그 대신에 한외여과법을 사용한 실시예 1, 2, 8과 역시 유해물질인 초산납을 사용아니한 비교예 2의 경우를 같은 조건에서 대비해 보기위해 각각 첨부도면 제1도, 제2도 및 제3도로 비교하였다.Among them, Examples 1, 2, and 8 using the ultrafiltration method instead of using the harmful substance lead acetate and Comparative Example 2, which also did not use the lead acetate which is also a hazardous substance, were prepared in the same conditions. Comparison was made with 1 degree, 2 degrees and 3 degrees.

이 결과로부터, 실시예 1, 2, 8의 경우 비교예 2에 비해 각각 크게 낮은 흡광도가 나타났음을 확인할 수 있다. 따라서, 본 발명의 경우 갖은 조건의 종래 것과 비교하여 프로안토시아니딘 화합물의 함량(잔류량)이 훨씬 낮음을 알 수 있다.From these results, it can be seen that in the case of Examples 1, 2, 8, significantly lower absorbance than each of Comparative Example 2. Therefore, in the case of the present invention, it can be seen that the content (residual amount) of the proanthocyanidin compound is much lower as compared with the conventional one having the conditions.

[시험방법][Test Methods]

은행잎에서 추출한 유효활성물질 20mg을 정밀히 달아 이소프로판올 : 3노르말 염산(5 : 1) 혼합용액에 녹여 25ml로 하고 여액 5ml를 취하여 10ml용량 플라스크에 옮기고 완전히 밀봉후 끓는 수욕상에서 45분간 가열하고 20℃에서 15분간 냉각하고 이소프로판올 : 3노르말 염산(5 : 1) 혼합용액을 가하여 표선을 채운다음 556nm에서 흡광도를 측정한다.20 mg of the active substance extracted from Ginkgo biloba are precisely weighed and dissolved in a mixed solution of isopropanol: 3 normal hydrochloric acid (5: 1) to make 25 ml. Take 5 ml of the filtrate and transfer to a 10 ml flask. After cooling for 10 minutes, add isopropanol: 3 normal hydrochloric acid (5: 1) mixed solution to fill the mark and measure the absorbance at 556 nm.

지표물질 프로안토시아니딘 0.5mg은 상기조건에 따라 10ml로 할때 0.477의 흡광도를 갖는다.0.5 mg of the indicator substance proanthocyanidins had an absorbance of 0.477 at 10 ml according to the above conditions.

실험예 2Experimental Example 2

상기 실시예 1∼8에서 얻어진 분말을 비교예 1과 비교예 2, 비교예 3 및 초산납 수용액으로 처리한 후 유기용매를 사용하는 추출공정을 시행하지 않은 비교예 4에서 얻어진 분말과 함께 다음 방법과 조건으로 고속액체 크로마토그라피(HPLC)를 이용하여 유효활성물질인 플라본 글리코사이드의 양을 정량적으로 분석하여 그 결과를 다음 표 2에 나타내었다.The powders obtained in Examples 1 to 8 were treated with Comparative Example 1, Comparative Example 2, Comparative Example 3, and lead acetate aqueous solution, and then the powders obtained in Comparative Example 4, which were not subjected to an extraction process using an organic solvent, Quantitative analysis of the amount of the active flavone glycoside as a quantitative analysis using high performance liquid chromatography (HPLC) as shown in Table 2 below.

또한, 본 발명의 방법에 따라 얻어진 유효활성물질의 성분에 대한 동질성 확인은 상기 실시예 2에서 얻어진 분말의 크로마토그램인 제4도와 표준품의 크로마토그램인 제5도를 통해 확인되었다.In addition, confirmation of homogeneity of the components of the active substance obtained according to the method of the present invention was confirmed through FIG. 4, which is a chromatogram of the powder obtained in Example 2, and FIG. 5, which is a chromatogram of a standard product.

[시험방법][Test Methods]

은행잎에서 추출한 유효활성물질 10mg을 정밀히 달아 메탄올 20ml에 용해시킨 후 염산 10ml을 가하고 끓는 수욕상에서 1시간 동안 가열하여 가수분해시키고 냉각 후 메탄올을 정확히 50ml로 하여 검액으로 하고 따로 퀘르세틴, 캠페롤, 이소람네틴 등의 지표물질을 사용하여 표준액을 만들고 고속액체 크로마토그라피로 분석하였다.10 mg of the active substance extracted from Ginkgo biloba is precisely weighed, dissolved in 20 ml of methanol, 10 ml of hydrochloric acid is added, and hydrolyzed by heating in a boiling water bath for 1 hour. After cooling, it is made into a sample solution with exactly 50 ml of methanol. Standard solutions were prepared using indicators such as netine and analyzed by high performance liquid chromatography.

[분석조건][Analysis Condition]

기기명 : Waters 6000A PumpInstrument: Waters 6000A Pump

Waters U6K InjectorWaters U6K Injector

Schimadzu Auto IntegratorSchimadzu auto integrator

A. 칼럼 : 3.9×150mm Nova-Pak C18, WatersA. Column: 3.9 × 150mm Nova-Pak C18, Waters

B. 이동상용매 : 물 : 메탄올 : 초산(60 : 40 : 3)B. Mobile Solvent: Water: Methanol: Acetic Acid (60: 40: 3)

C. 유속 : 1.0ml/minC. Flow Rate: 1.0ml / min

D. 검출기 : UV 365nmD. Detector: UV 365nm

E. 주입량 : 10μlE. Injection volume: 10μl

F. 감도 : 0.1Aufs.F. Sensitivity: 0.1Aufs.

G. 기록지감도 : 0.1cm/minG. Record Sensitivity: 0.1cm / min

상기 분석결과로부터 본 발명의 추출정제방법에 따른 실시예(한외여과법)의 경우 한외여과법을 실시하지 않은 상태인 비교예 1이나 납화합물을 사용하지 아니한 비교예 2(일본특허공고 소46-28091호)에 비해 프로안토시아니딘의 함량이 크게 줄어든 것을 확인할 수 있다.In the case of the embodiment (ultrafiltration method) according to the extraction and purification method of the present invention from the analysis results, Comparative Example 1 in which the ultrafiltration method was not performed or Comparative Example 2 without using a lead compound (Japanese Patent Publication No. 46-28091) It can be seen that the content of proanthocyanidins is significantly reduced compared to).

또한, 본 발명의 실시예(한외여과법)와 유해성분인 납화합물을 사용한 비교예 3(일본특허공고 소49-27323)을 비교해 보면, 유해물질인 초산납을 사용한다는 점에서도 비교예 3에 비해 실시예가 우수한 것이지만, 본 발명의 방법인 실시예에서는 단한번의 간단한 한외여과 방식을 사용하는 대신에 비교예 3에서는 95v/v% 에탄올 100ml 사용, 10v/v% 초산납 30ml 사용, 여과, 농축, 60v/v% 에탄올 사용, 황산암모늄 사용, 교반, 여과, 메틸에틸케톤과 아세톤 혼합용매로 3회 추출등의 복잡한 공정을 거치는 불리한 방법을 사용하고서도 수율이나 프로안토시아니딘 함량(잔류율)에서 실시예에 비해 거의 같은 수준으로 유지할 뿐이므로, 이로부터 본 발명의 방법은 공정단축 및 유해물질 불사용의 진보된 효과가 있음을 확인할 수 있다.In addition, when comparing the Example (Ultrafiltration method) of the present invention with Comparative Example 3 (Japanese Patent Publication No. 49-27323) using a lead compound as a harmful component, it was carried out in comparison with Comparative Example 3 in that it used lead acetate as a hazardous substance. Although the example is excellent, in Example, the method of the present invention uses 100 ml of 95v / v% ethanol, 30ml of 10v / v% lead acetate in Comparative Example 3, instead of using only one simple ultrafiltration, filtration, concentration, 60v / Example in terms of yield or proanthocyanidin content (remaining rate), even using unfavorable methods such as v% ethanol use, ammonium sulfate use, stirring, filtration, three times extraction with methyl ethyl ketone and acetone mixed solvent. Since it is only maintained at about the same level as compared to this, it can be seen that the method of the present invention has an advanced effect of shortening the process and using no harmful substances.

또, 납화합물을 사용한 상기 비교예 3과 같은 방법으로 실시하되 실시예에서의 한외여과법 대신 초산납과 에탄올을 이용하여 추출하고 그 외의 공정을 시행하지 아니한 비교예 4의 경우에는, 본 발명의 실시예에 비해 유효활성물질의 함량이 크게 낮고 수율도 크게 낮아진 것을 알 수 있는 바, 여기서 프로안토시아니딘 함량이 낮게 나타난 것은 유효활성물질과 수율이 낮아지므로서 당연히 프로안토시아니딘 함량도 낮게 측정된 것이므로 어느면으로나 본 발명에 비해 효과가 크게 떨어진다는 것을 확인할 수 있게 된다.In addition, in the case of Comparative Example 4, which is carried out in the same manner as in Comparative Example 3 using a lead compound but extracted with lead acetate and ethanol instead of the ultrafiltration method in Example, and no other processes were carried out, Examples of the present invention It can be seen that the content of the active active material is significantly lower and the yield is significantly lower than that of the present invention. The low content of proanthocyanidin is low in the active active material and the yield is low, and therefore, the proanthocyanidin content is also low. It is possible to confirm that the effect is greatly reduced compared to the present invention in any aspect.

위 결과로부터, 본 발명은 종래의 방법에 비해 유효활성물질을 사용하지 아니하면서도 공정을 크게 단축시켰고 고순도, 고수율의 은행잎 추출물을 얻을 수 있는 것임을 알 수 있으며, 특히 목적하는 총유효활성물질 수득량을 비교해 보면 본 발명의 방법은 그 순도 뿐아니라 수율에서도 크게 개선되었음을 알 수 있다.From the above results, it can be seen that the present invention can significantly reduce the process and obtain a high purity, high yield of ginkgo biloba extract without using an active substance compared to the conventional method, in particular, the desired total active substance yield Comparing to the method of the present invention can be seen that greatly improved not only in the purity but also the yield.

한편, 상기 실시예 1∼8과 비교하여 참고예의 경우 한외여과법을 사용하되 배제한계가 1,000달톤인 것을 사용한 것으로서 수율이 실시예에 비해 떨어지는 것을 알 수 있으므로 한외여과막의 배제한계가 3,000달톤 이상의 경우가 바람직함을 확인할 수 있고, 또 실시예 8의 경우에는 배제한계가 10,000달톤인 것을 사용하였을때 프로안토시아니딘의 함량이 다른 실시예에 비해 다소 증가된 것으로 보아 10,000달톤 보다 높은 배제한계를 갖는 한외여과막을 사용하면 바람직하지 않음을 확인할 수 있다.On the other hand, in the case of the reference example compared to Examples 1 to 8, the ultrafiltration method was used, but the exclusion limit was 1,000 Daltons, and the yield was lower than that of the Example, so the ultrafiltration membrane exclusion limit was 3,000 Daltons or more. In the case of Example 8, when the exclusion limit was used at 10,000 Daltons, the content of proanthocyanidin was slightly increased compared to the other examples, so that the exclusion limit was higher than 10,000 Daltons. It can be seen that the use of an ultrafiltration membrane is undesirable.

Claims (1)

은행잎을 메탄올이나 물과 아세톤 또는 알코올의 혼합용액으로 초기 추출하고 무기염을 가한 다음, 유기용매로 다시 추출한 후, 얻어진 조엑기스로부터 불순물을 제거하여 유효활성물질을 추출정제함에 있어서, 상기 조엑기스를 감압농축하여 얻은 잔류물에 50v/v% 농도의 에탄올 수용액을 첨가하여 고형성분이 5∼20중량%가 되게한 다음 4기압의 압력조건에서 배제한계가 3,000∼10,000달톤인 한외여과막을 통과시켜 단백질, 다당 및 프로안토시아니딘 성분을 제거함을 특징으로 하는 은행잎으로부터 유효활성물질을 추출정제하는 방법.The ginkgo biloba leaves are initially extracted with a mixed solution of methanol, water, acetone or alcohol, added with an inorganic salt, and then extracted again with an organic solvent. The crude extract is then extracted and purified by removing impurities from the obtained crude extract. A 50v / v% aqueous ethanol solution was added to the residue obtained by concentration under reduced pressure, so that the solid component was 5-20% by weight, and the protein was passed through an ultrafiltration membrane having a limit of 3,000-10,000 Daltons at 4 atm. And extracting and purifying the active substance from ginkgo biloba leaves, characterized in that it removes polysaccharide and proanthocyanidin components.
KR1019920022987A 1992-12-01 1992-12-01 Method of extraction and purification for active substances from ginko herb KR960010622B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019920022987A KR960010622B1 (en) 1992-12-01 1992-12-01 Method of extraction and purification for active substances from ginko herb

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019920022987A KR960010622B1 (en) 1992-12-01 1992-12-01 Method of extraction and purification for active substances from ginko herb

Publications (2)

Publication Number Publication Date
KR940013519A KR940013519A (en) 1994-07-15
KR960010622B1 true KR960010622B1 (en) 1996-08-06

Family

ID=19344452

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920022987A KR960010622B1 (en) 1992-12-01 1992-12-01 Method of extraction and purification for active substances from ginko herb

Country Status (1)

Country Link
KR (1) KR960010622B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101502514B1 (en) * 2012-11-22 2015-03-13 (주)다인내추럴 Compositions for improving blood circulation and blood-lipids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101502514B1 (en) * 2012-11-22 2015-03-13 (주)다인내추럴 Compositions for improving blood circulation and blood-lipids

Also Published As

Publication number Publication date
KR940013519A (en) 1994-07-15

Similar Documents

Publication Publication Date Title
EP2842957B1 (en) Method for extracting and separating ginkgolides
CN105037300B (en) A kind of method for extracting fucoxanthin and brown algae polyphenols comprehensive from sargassum
KR0154984B1 (en) Extract from leaves of ginko biloba and their processes for preparing ampule containing them
EP0535001B1 (en) Composite molecular system for the contra-escalatory treatment of viral infections
KR101393359B1 (en) Grape seeds extracts obtainable by fractioning on a resin
KR0169957B1 (en) New extracts of ginkgo biloba and their method of preparation
JPH0399090A (en) Method for preparation of extract containing highly pure anthocyanosides from plant or its extract
US9827262B2 (en) Rutin-rich extract and method of making same
CN112841643A (en) Method for solubilizing hydrophobic polyphenol by using hydrophilic polyphenol
KR960010622B1 (en) Method of extraction and purification for active substances from ginko herb
JPH07330596A (en) Antitumor agent
KR940011917B1 (en) Method of extractron of panax ginseng flavonoides
WO2012101008A1 (en) Process for the production of proanthocyanidin polymeric composition
DE112005001269T5 (en) Lycium barbarum polysaccharide extract as a neuroprotective agent against β-amyloid peptide neurotoxicity
CN101683363B (en) Composition preparation of ginkgo biloba extract and dipyridamole and preparation method thereof
CN106420530A (en) Plant extract liquid composition with skin protecting and conditioning functions and method for preparing plant extract liquid composition
FI98889C (en) A method for preparing an antineoplastic drug derived from a plant extract
CN111748024A (en) Preparation method of periplaneta americana polypeptide
JP2002519383A (en) Water-soluble natural plant dry extract, especially ginkgo extract with high content of terpenoids and flavone glycosides
KR100893779B1 (en) The extracting method of Angelica gigas Nakai that has effect of scavenging action on free radical
US4985247A (en) Pharmaceutical composition for inhibiting viruses and increasing immune function (PII)
Khoiroh et al. The Potential of Pineapple Crown (Ananas Comosus) as Removal of Kidney Stone
KR100780056B1 (en) Method of extracting ginsengnoside rg2, pharmaceutical composition including ginsengnoside rg2, and uses thereof
JPH06100584A (en) New flavonoid glycoside
KR950005738B1 (en) Separation and purification of polysaccharide with nitrogen from taraxaci radix

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19990721

Year of fee payment: 17

EXPY Expiration of term